A number of other equities research analysts have also recently weighed in on CDLX. Zacks Investment Research cut Cardlytics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 9th. TheStreet cut Cardlytics from a “c-” rating to a “d” rating in a research note on Wednesday, March 18th. Bank of America reaffirmed an “average” rating and issued a $100.00 price objective on shares of Cardlytics in a research note on Tuesday, January 14th. Raymond James cut Cardlytics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 15th. They noted that the move was a valuation call. Finally, Craig Hallum cut Cardlytics from a “buy” rating to a “hold” rating and lowered their target price for the stock from $100.00 to $70.00 in a research note on Wednesday, March 4th. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $66.57.
Shares of NASDAQ CDLX opened at $42.88 on Friday. Cardlytics has a twelve month low of $14.14 and a twelve month high of $107.50. The stock has a fifty day simple moving average of $70.10 and a 200-day simple moving average of $57.93. The stock has a market capitalization of $901.92 million, a PE ratio of -54.97 and a beta of 1.64.
Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported $0.18 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.14. Cardlytics had a negative return on equity of 19.49% and a negative net margin of 8.15%. The business had revenue of $69.29 million during the quarter, compared to analysts’ expectations of $69.19 million. During the same period in the previous year, the firm posted ($0.06) earnings per share. The company’s revenue was up 44.9% on a year-over-year basis. As a group, analysts expect that Cardlytics will post -0.63 EPS for the current year.
In related news, major shareholder Clifford Sosin bought 181,621 shares of the stock in a transaction that occurred on Monday, March 23rd. The stock was purchased at an average cost of $29.52 per share, with a total value of $5,361,451.92. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kirk Somers sold 5,562 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $99.66, for a total value of $554,308.92. Following the transaction, the insider now directly owns 76,455 shares of the company’s stock, valued at $7,619,505.30. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 489,926 shares of company stock valued at $17,936,867 and have sold 283,638 shares valued at $22,698,360. Insiders own 21.90% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. FMR LLC boosted its position in shares of Cardlytics by 5.7% during the 4th quarter. FMR LLC now owns 3,856,756 shares of the company’s stock worth $242,436,000 after acquiring an additional 207,626 shares in the last quarter. CAS Investment Partners LLC boosted its position in shares of Cardlytics by 21.7% during the 4th quarter. CAS Investment Partners LLC now owns 2,821,710 shares of the company’s stock worth $177,373,000 after acquiring an additional 502,299 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Cardlytics by 351.1% during the 4th quarter. Bank of New York Mellon Corp now owns 440,251 shares of the company’s stock worth $27,673,000 after acquiring an additional 342,660 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Cardlytics by 17.6% during the 4th quarter. Bank of America Corp DE now owns 384,977 shares of the company’s stock worth $24,200,000 after acquiring an additional 57,595 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Cardlytics by 266.4% during the 4th quarter. Renaissance Technologies LLC now owns 377,135 shares of the company’s stock worth $23,707,000 after acquiring an additional 274,200 shares in the last quarter.
Cardlytics Company Profile
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Further Reading: Call Option Volume
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.